NASDAQ:MRSN
Mersana Therapeutics, Inc. Stock News
$2.58
+0.0100 (+0.389%)
At Close: May 16, 2024
Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
06:00am, Friday, 06'th Aug 2021
CAMBRIDGE, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates
08:00am, Friday, 30'th Jul 2021
CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
02:13am, Tuesday, 29'th Jun 2021
Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Mersana Therapeutics, Inc.'s (MRSN) CEO Anna Protopapas on Q1 2021 Results - Earnings Call Transcript
10:54pm, Monday, 10'th May 2021
Mersana Therapeutics, Inc.'s (MRSN) CEO Anna Protopapas on Q1 2021 Results - Earnings Call Transcript
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
06:47pm, Monday, 10'th May 2021
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -28.21% and -95.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the
Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
04:01pm, Monday, 10'th May 2021
- Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer - Ended first quarter of 2021 with $228 million in cash
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates
08:00am, Monday, 03'rd May 2021
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer Patients
10:17am, Friday, 09'th Apr 2021
Mersana Therapeutics Inc (NASDAQ: MRSN) has initiated patient dosing in the UPLIFT study evaluating upifitamab rilsodotin in patients with ovarian cancer. The single-arm registration strategy will
Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Moving Average Crossover Alert: Mersana Therapeutics (MRSN)
07:13am, Friday, 12'th Mar 2021
Mersana Therapeutics (MRSN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Mersana Therapeutics to Present Three Posters at Upcoming Virtual 2021 American Association for Cancer Research Annual Meeting
04:35pm, Wednesday, 10'th Mar 2021
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics, Inc.'s (MRSN) CEO Anna Protopapas on Q4 2020 Results - Earnings Call Transcript
01:33pm, Friday, 26'th Feb 2021
Mersana Therapeutics, Inc.'s (MRSN) CEO Anna Protopapas on Q4 2020 Results - Earnings Call Transcript
